Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Int Immunopharmacol ; 110: 108952, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35716482

ABSTRACT

Visceral leishmaniasis (VL) is an infectious disease caused by Leishmania infantum (L. infantum). Currently, there are no vaccines and/or prophylactic therapies against VL, and the recentpharmacological approaches come from the drug repositioning strategy. Here, we evaluated the anticancer drug pamidronate (PAM) to identify a new therapeutic option for the treatment of human VL. We assessed its in vitro antileishmanial activity against the promastigote and amastigote forms of L. infantum by evaluating cell cytotoxicity. The antileishmanial and immunomodulatory activities were assessed using human peripheral blood leukocytes ex vivo. PAM induced the formation of vacuoles in the cytoplasm of the promastigotes and alterations in the morphology of the kinetoplast and mitochondria in vitro, which indicates anti-promastigote activity. PAM also reduced the number of infected macrophages and intracellular amastigotes in a concentration-dependent manner, with cell viability above 70%. In ex vivo, PAM reduced the internalized forms of L. infantum in the classical monocyte subpopulation. Furthermore, it enhanced IL-12 and decreased IL-10 and TGF-ß by monocytes and neutrophils. Increased IFN-γ and TNF levels for CD8- and CD8+ T lymphocytes and B lymphocytes, respectively, were observed after the treatment with PAM, as well as a reduction in IL-10 by the lymphocyte subpopulations evaluated. Taken together, our results suggest that PAM may be eligible as a potential therapeutic alternative for drug repurposing to treat human visceral leishmaniasis.


Subject(s)
Antiprotozoal Agents , Leishmania infantum , Leishmaniasis, Visceral , Leishmaniasis , Animals , Antiprotozoal Agents/pharmacology , Antiprotozoal Agents/therapeutic use , Drug Repositioning , Humans , Interleukin-10/therapeutic use , Leishmaniasis/drug therapy , Leishmaniasis, Visceral/drug therapy , Mice , Mice, Inbred BALB C , Pamidronate
2.
Parasite Immunol ; 41(11): e12668, 2019 11.
Article in English | MEDLINE | ID: mdl-31494949

ABSTRACT

AIMS: The aim of the study was to evaluate the immune response triggered by the first contact of human monocytes with two T cruzi strains from distinct discrete typing units (DTUs) IV and V, and whether co-infection with these strains leads to changes in monocyte immune profiles, which could in turn influence the subsequent infection outcome. METHODS AND RESULTS: We evaluated the influence of in vitro single- and co-infection with AM64 and 3253 strains on immunological characteristics of human monocytes. Single infection of monocytes with AM64 or 3253 induced opposing anti-inflammatory and inflammatory responses, respectively. Co-infection was observed in over 50% of monocytes after 15 hours of culture, but this percentage dropped ten-fold after 72 hours. Co-infection led to high monocyte activation and an increased percentage of both IL-10 and TNF. The decreased percentage of co-infected cells observed after 72 hours was associated with a decreased frequency of TNF-expressing cells. CONCLUSION: Our results show that the exacerbated response observed in co-infection with immune-polarizing strains is associated with a decreased frequency of co-infected cells, suggesting that the activated response favours parasite control. These findings may have implications for designing new Chagas disease preventive strategies.


Subject(s)
Chagas Disease/immunology , Monocytes/immunology , Trypanosoma cruzi/classification , Trypanosoma cruzi/immunology , Adolescent , Adult , Cells, Cultured , Chagas Disease/parasitology , Coinfection , Humans , Interleukin-10/metabolism , Middle Aged , Tumor Necrosis Factor-alpha/metabolism , Young Adult
3.
Immunobiology ; 224(4): 518-525, 2019 07.
Article in English | MEDLINE | ID: mdl-31109749

ABSTRACT

Hansen's disease (or leprosy) still persists as a serious public health issue. Its diagnosis is based primarily on the detection of clinical signs that are characteristic of the disease. Studies have pointed to the selection of a set of serological and cellular biomarkers of subclinical infection that result in an efficient diagnosis. The aim of this study was compare index cases and their household contacts to identify differentially expressed biomarkers of immune response in leprosy that could provide reliable evidence of subclinical infection in household contacts. The study population consisted of index cases with multibacillary form (IC, n = 13) and their household contacts (HC, n = 14). Serum cytokines and chemokines were quantified using the cytometric beads array (CBA) system. The humoral response was assessed by ELISA test. Flow cytometry was used to characterize the cellular immune response. Monocyte and CD4 + T lymphocytes frequency was significantly higher in IC. Both CD4+ and CD8 + T lymphocytes had a reduced CD25 expression in HC. The immunoglobulin (Ig)M profile anti- NDO-HSA, LID-1, and NDOLID antigens was significantly higher in IC. This study points to the monocyte and CD4+ lymphocyte frequency, as well as specific IgM profile, as predictors of subclinical infection in the household contacts.


Subject(s)
Biomarkers , Family , Leprosy/diagnosis , Leprosy/immunology , Adolescent , Adult , Aged , Child , Child, Preschool , Cross-Sectional Studies , Cytokines/blood , Female , Humans , Immunoglobulin M/immunology , Infant , Leprosy/microbiology , Leprosy/transmission , Leukocytes/immunology , Leukocytes/metabolism , Male , Middle Aged , Mycobacterium leprae/immunology , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...